PRALATREXATE - Generic Drug Details

What are the generic sources for pralatrexate and what is the scope of freedom to operate?

Pralatrexate is the generic ingredient in two branded drugs marketed by Acrotech Biopharma and Dr Reddys, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for pralatrexate. Three suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for PRALATREXATE

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	62
Clinical Trials:	43
Patent Applications:	7,999
What excipients (inactive ingredients) are in PRALATREXATE?	PRALATREXATE excipients list
DailyMed Link:	PRALATREXATE at DailyMed

Recent Clinical Trials for PRALATREXATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fred Hutchinson Cancer Center	PHASE1
Corvus Pharmaceuticals, Inc.	PHASE3
Dizal Pharmaceuticals	PHASE3

See all PRALATREXATE clinical trials

Generic filers with tentative approvals for PRALATREXATE

Applicant	Application No.	Strength	Dosage Form
		40MG/2ML	INJECTABLE;INJECTION
		20MG/1ML	INJECTABLE;INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for PRALATREXATE

Drug Class

Folate Analog Metabolic Inhibitor

Anatomical Therapeutic Chemical (ATC) Classes for PRALATREXATE

L01BA	Folic acid analogues
L01B	ANTIMETABOLITES
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for PRALATREXATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FOLOTYN	Injection	pralatrexate	20 mg/mL and 40 mg/2 mL	022468	4	2013-09-24

US Patents and Regulatory Information for PRALATREXATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-001	Sep 24, 2009	AP	RX	Yes	No
Dr Reddys	PRALATREXATE	pralatrexate	SOLUTION;INTRAVENOUS	206183-001	Mar 10, 2025	AP	RX	No	No
Dr Reddys	PRALATREXATE	pralatrexate	SOLUTION;INTRAVENOUS	206183-002	Mar 10, 2025	AP	RX	No	No
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-002	Sep 24, 2009	AP	RX	Yes	Yes

Expired US Patents for PRALATREXATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-001	Sep 24, 2009
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-001	Sep 24, 2009
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-002	Sep 24, 2009
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-002	Sep 24, 2009

EU/EMA Drug Approvals for PRALATREXATE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Allos Therapeutics Ltd	Folotyn	pralatrexate	EMEA/H/C/002096treatment of peripheral T-cell lymphoma,	Refused	no	no	yes		2012-06-21

Pralatrexate (PRALATREXATE): Market dynamics and financial trajectory

Last updated: May 7, 2026

How does pr alatrexate perform commercially across time and indication?

Pralatrexate is a folate analog (antimetabolite) positioned in oncology for rare patient populations. In the US, it is marketed under the brand Folotyn. The drug’s commercial trajectory has been dominated by the size of its target disease segment (relapsed or refractory peripheral T-cell lymphoma) and by post-launch treatment-line shifts driven by competing therapies.

Core market anchor

• Indication footprint: relapsed or refractory peripheral T-cell lymphoma (PTCL), including PTCL, not otherwise specified and angioimmunoblastic T-cell lymphoma (as supported by label history and clinical positioning used for reimbursement and uptake).
• Mechanism that shapes adoption: folate receptor-mediated uptake and intracellular retention, with a dosing and administration model that can be operationally more demanding than some oral or less frequent regimens. That affects real-world persistence and payer acceptance.

US pricing and reimbursement dynamics

• Pralatrexate’s US market has historically moved with:
  1. Reimbursement restrictiveness (oncology drugs frequently face line-of-therapy and authorization controls),
  2. Dose intensity and supportive care requirements (folate supplementation and monitoring practices),
  3. Competition for salvage/next-line slots from newer PTCL therapies with broader use-cases or better tolerability profiles for clinicians.

Global market pattern

• Europe and other markets typically lag the US for oncology uptake due to slower reimbursement decisions and tighter evidence thresholds.
• For oncology niche drugs like pralatrexate, revenue is more sensitive to:
  • local reimbursement criteria and restricted patient access,
  • distribution channel economics,
  • the life cycle pace of competitor approvals rather than pure label expansion.

What market forces shape pralatrexate demand?

The market around pralatrexate is driven by a narrow oncology niche plus a “replacement risk” profile common to cytotoxic and targeted-content oncology agents.

Demand drivers

• Clinical need in relapsed/refractory PTCL: PTCL is small-volume but high-acuity, with limited effective options in salvage settings early in the product life cycle.
• Defined line-of-therapy positioning: pralatrexate often captures patients who need a recognized regimen after prior systemic treatment.
• Clinician familiarity and protocolization: once dosing and supportive care are embedded in practice, adoption stabilizes until a stronger competing regimen displaces it.

Replacement risks

• Therapy innovation in PTCL: each new approval that improves response rates, durability, tolerability, or convenience tends to redistribute patient flow away from older salvage options.
• Payer scrutiny as revenues rise: once a drug’s price and budget impact are understood, payers tend to enforce criteria more strictly, especially in rare cancers where comparative cost-effectiveness must justify broader use.
• Treatment sequencing changes: real-world practice often shifts when clinicians gain confidence in newer combinations or targeted therapies for earlier use.

What does the financial trajectory look like for Folotyn/pralatrexate?

Pralatrexate’s financial trajectory follows a typical pattern for a rare-cancer oncology product: launch-to-peak buildup, then a gradual compression as new therapies enter and payer access tightens.

Trajectory phases

1. Launch and uptake ramp

   • Demand concentrates in centers that treat PTCL and manage salvage protocols.
   • Revenue scales with time-to-reimbursement and clinician adoption.

2. Maturity with constrained volumes

   • As PTCL patient flow remains limited, revenues track incremental treatment-line penetration rather than broad market growth.
   • Reimbursement practices stabilize; growth becomes modest.

3. Competitive erosion

   • As competing PTCL therapies gain share, pralatrexate volumes decline in salvage lines.
   • Revenue falls even when per-patient economics remain stable, because the dominant driver becomes patient share.

4. Late-life stabilization or further decline

   • For established niche oncology drugs, revenue often stabilizes at a low baseline once displacement is complete and access criteria limit out-of-label or less formal use.

What controls revenue direction

• Patient share in PTCL salvage: the key determinant of revenue changes more than price alone.
• Payer authorization strictness: prior-therapy thresholds and evidence-based criteria reduce eligible populations.
• Treatment switching behavior: when clinicians adopt new regimens, the displacement is relatively fast once benefits are perceived.

What is the patent and lifecycle context affecting financial outlook?

Pralatrexate sits within a life cycle where patent coverage and exclusivity windows define the ceiling for long-term revenue, while competitive approvals define the slope during exclusivity.

Exclusivity and long-term risk

• US market exclusivity and patent estate influence pricing power, but in rare cancers the bigger driver is often therapy displacement rather than generic entry risk.
• Bios and targeted therapies pipeline raise competitive pressure even during patent-protected periods.

How do investors and R&D decision-makers should model commercialization outcomes?

For a niche oncology agent, commercialization is best modeled as a patient-share problem with payer constraints, not a broad market expansion story.

Key quantitative model levers

• Eligible patient pool size (PTCL salvage): drives the “ceiling” revenue potential.
• Treatment line conversion rate: what fraction of eligible patients start pralatrexate rather than an alternative.
• Authorization rate: payer approvals as a fraction of requests.
• Dose persistence and discontinuation: practical treatment duration affects drug volume per patient.
• Competitive share drift: the speed of displacement after competitor approvals.

Scenario structure

• Base case: modest decline in patient share with stabilization after uptake of a few competing regimens.
• Downside: accelerated displacement if new therapies move earlier in salvage or show strong tolerability advantages.
• Upside: label expansion or changes in sequencing that create new entry points (historically less common for niche agents unless strong evidence supports it).

What actionable conclusions follow from the market dynamics?

• Pralatrexate’s commercial model is defined by small-volume PTCL salvage demand, meaning growth comes slowly and declines can be persistent once competitor regimens take share.
• Pricing power is necessary but not sufficient; payer access and sequencing define net revenue performance.
• The financial trajectory should be treated as a share decay curve rather than a volume growth curve.

---

Key Takeaways

• Pralatrexate (Folotyn) sells into a narrow PTCL salvage population, so the market ceiling is structurally limited.
• Revenue direction is driven primarily by patient share in salvage lines and by payer authorization controls, not by broad demand expansion.
• The financial trajectory follows a launch-to-maturity-to-erosion pattern common in rare oncology, with competitive therapy approvals exerting the dominant long-term pressure.
• For planning, model pralatrexate as a patient-share and persistence product under constrained eligibility, with competitive displacement as the central downside driver.

FAQs

1. What indication drives most pralatrexate revenue?
   Relapsed or refractory peripheral T-cell lymphoma (PTCL) in salvage settings, marketed in the US as Folotyn.

2. Why does pralatrexate face commercial pressure over time?
   PTCL is small-volume and clinicians often shift to newer regimens, so patient share erodes as competitive therapies gain uptake.

3. What is the biggest lever behind revenue changes?
   Eligible patient share in the relevant line of therapy, shaped by payer criteria and treatment sequencing.

4. Does pricing dominate the revenue outlook?
   Pricing matters, but in practice for niche oncology drugs, access and share dominate the revenue trajectory.

5. How should R&D and investment teams frame future performance?
   Use a share-decay model anchored on the PTCL salvage population, adjusted for authorization rate and competitive displacement speed.

---

References

[1] FDA. “Folotyn (pralatrexate) prescribing information.” U.S. Food and Drug Administration.
[2] NCI. “Peripheral T-Cell Lymphoma.” National Cancer Institute, overview and treatment context.
[3] European Medicines Agency (EMA). “Folotyn (pralatrexate) product information.” European public assessment and prescribing documentation.